(1→3)-β-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease

Clinical and Experimental Rheumatology

Volumn 23, Issue 5, 2005, Pages 678-680

  Shimizu, Atushi ^a   Oka, Hiroshi ^a   Matsuda, Takahide ^a   Ozaki, Shoichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

(1 3) D glucan; Connective tissue disease; Pneumocycstis carinii pneumonia

Indexed keywords

AZATHIOPRINE; BETA 1,3 GLUCAN; BIOLOGICAL MARKER; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; STEROID; BETA GLUCAN; BETA-1,3-GLUCAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REGIMEN; FEMALE; HUMAN; HYPOALBUMINEMIA; MALE; MEDICAL RECORD; OUTCOMES RESEARCH; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS NODOSA; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SJOEGREN SYNDROME; SURVIVAL RATE; SYSTEMIC SCLEROSIS; BLOOD; MIDDLE AGED;

ADULT; AGED; BETA-GLUCANS; BIOLOGICAL MARKERS; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 24944580960     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. YALE SH, LIMPER AH: Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 5-13.
2. GODEAU B, COUTANT-PERRONNE V, LE THI HUONG D et al.: Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994; 21: 246-51.
3. KOVACS JA, HIEMENZ JW, MACHER AM et al.: Pnumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100: 663-71.
4. ANDREW JP, SUSANNAH LB, CHRISTOPHER R et al.: Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol 1992; 19: 1191-4.
5. KADOYA A, OKADA J, IIKUNI Y et al.: Risk factors for Pneumocystis carinii pneumonia in patients polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996; 23: 1186-8.
6. EDMAN JC, KOVACS JA, MASUR H, SANTI DV, ELWOOD HJ, SOGIN ML: Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334: 519-22.
7. KOTTOM TJ, LIMPER AH: Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition. J Biol Chem 2000; 275: 40628-34.
8. OBAYASHI T, YOSHIDA M, MORI T et al.: Plasma (1→3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
9. WAKEFIELD AE, PIXLEY FJ, BANERJI S et al.: Detection of Pneumocystis carinii with DNA amplification. Lancet 1990; 336: 451-3.
10. YASUOKA A, TACHIKAWA N, SHIMADA K, KIMURA S, OKA S:(1→3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3:197-9.
11. OKAMOTO K, YAMAMOTO T, NONAKA D et al.: Plasma (1→3)-beta-D-glucan measurement and polymerase chain reaction on sputum as practical parameters in Pneumocystis carinii pneumonia. Intern Med (Tokyo, Japan) 1998; 37: 618-21.
12. SAITO K, NAKAYAMADA S, NAKANO K et al.: Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases re-evaluation of clinical features of Pneumocystis carinii pneumonia in rheumatic diseases. Rheumatology 2004; 43: 479-85.
13. VENTO S, DI PERRI G, GAROFANO T, CONCIA E, BASSETTI D: Pneumocystis carinii pneumonia during primary HIV-1 infection. Lancet 1993; 342: 24-5.
14. CRUCIANI M, MARCATI P, MALENA M, BOSCO O, SERPELLONI G, MENGOLI C: Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002; 20: 982-9.
15. PARA MF, FINKELSTEIN D, BECKER S, DOHN M, WALAWANDER A, BLACK JR: Reduced toxicity with gradual initiation of trimethoprim-surfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr 2000; 24: 337-43.